Gasgon | Development of a Novel Medical Device to Remove Air Bubbles from Medicines, Which Will Improve Patient Safety and Reduce Costs of IV Infusion

Summary
Over 2 billion medical intravenous (IV) infusions occur each year globally, with over 80% of inpatients receiving IV treatment. Each of these infusions carry a serious health risk – the risk that gas bubbles enter with the fluid and block blood flow in patients. Air Embolism, a potentially deadly complication of IV infusion, is a result of bubbles entering the venous system and blocking blood flow leading to serious adverse complications for patients such as Sepsis, Stroke, Brain Dysfunction and Heart Attack. In extreme cases death can occur. Gasgon Medical has built a break-through and disruptive technology to reduce risk and optimise fluid management in common medical IV treatments. Currently clinicians must intervene to remove every bubble in every infusion, a labour-intensive practice that puts a strain on healthcare resources, with wasted man-hours and reduced efficacy of the medicine dose. Technology solutions on the market include electronic alarms and in-line filters – these are unsuitable in the majority of cases and place a significant human and financial burden on healthcare providers. Our innovation, which is a new form of ‘vent’ technology, will solve this unmet clinical need. Gasgon Medical has invented the first mechanical, in-line, automatic vent capable of removing bubbles from IV fluids regardless of position or environment. Our Patent-pending disposable vent acts quickly and reliably without interrupting or reducing the prescribed dose of medications. This represents a major technology advancement over current methods of managing risk in IV infusions. Gasgon Medical can lead a €220mn IV vent opportunity bringing an exciting European innovation to the global market. This novel Gasgon vent technology has the potential to positively impact healthcare delivery and performance, leading to better patient outcomes.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/887764
Start date: 01-01-2020
End date: 30-06-2020
Total budget - Public funding: 71 429,00 Euro - 50 000,00 Euro
Cordis data

Original description

Over 2 billion medical intravenous (IV) infusions occur each year globally, with over 80% of inpatients receiving IV treatment. Each of these infusions carry a serious health risk – the risk that gas bubbles enter with the fluid and block blood flow in patients. Air Embolism, a potentially deadly complication of IV infusion, is a result of bubbles entering the venous system and blocking blood flow leading to serious adverse complications for patients such as Sepsis, Stroke, Brain Dysfunction and Heart Attack. In extreme cases death can occur. Gasgon Medical has built a break-through and disruptive technology to reduce risk and optimise fluid management in common medical IV treatments. Currently clinicians must intervene to remove every bubble in every infusion, a labour-intensive practice that puts a strain on healthcare resources, with wasted man-hours and reduced efficacy of the medicine dose. Technology solutions on the market include electronic alarms and in-line filters – these are unsuitable in the majority of cases and place a significant human and financial burden on healthcare providers. Our innovation, which is a new form of ‘vent’ technology, will solve this unmet clinical need. Gasgon Medical has invented the first mechanical, in-line, automatic vent capable of removing bubbles from IV fluids regardless of position or environment. Our Patent-pending disposable vent acts quickly and reliably without interrupting or reducing the prescribed dose of medications. This represents a major technology advancement over current methods of managing risk in IV infusions. Gasgon Medical can lead a €220mn IV vent opportunity bringing an exciting European innovation to the global market. This novel Gasgon vent technology has the potential to positively impact healthcare delivery and performance, leading to better patient outcomes.

Status

CLOSED

Call topic

EIC-SMEInst-2018-2020

Update Date

26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
H2020-EU.2.1.0. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Cross-cutting calls
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1
H2020-EU.2.3. INDUSTRIAL LEADERSHIP - Innovation In SMEs
H2020-EU.2.3.0. INDUSTRIAL LEADERSHIP - Innovation In SMEs - Cross-cutting calls
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.0. Cross-cutting call topics
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1